Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Rationale: Recent clinical trial successes have created an urgent need for earlier and more sensitive endpoints of disease progression in idiopathic pulmonary fibrosis (IPF). Domiciliary spirometry permits more frequent measurement of FVC than does hospital-based assessment, which therefore affords the opportunity for a more granular insight into changes in IPF progression. Objectives: To determine the feasibility and reliability of measuring daily FVC in individuals with IPF. Methods: Subjects with IPF were given handheld spirometers and instruction on how to self-administer spirometry. Subjects recorded daily FEV1 and FVC for up to 490 days. Clinical assessment and hospital-based spirometry was undertaken at 6 and 12 months, and outcome data were collected for 3 years. Measurements and Main Results: Daily spirometry was recorded by 50 subjects for a median period of 279 days (range, 13–490 d). There were 18 deaths during the active study period. Home spirometry showed excellent correlation with hospital-obtained readings. The rate of decline in FVC was highly predictive of outcome and subsequent mortality when measured at 3 months (hazard ratio [HR], 1.040; 95% confidence interval [CI], 1.021–1.062; P ≤ 0.001), 6 months (HR, 1.024; 95% CI, 1.014–1.033; P < 0.001), and 12 months (HR, 1.012; 95% CI, 1.007–1.016; P = 0.001). Conclusions: Measurement of daily home spirometry in patients with IPF is highly clinically informative and is feasible to perform for most of these patients. The relationship between mortality and rate of change of FVC at 3 months suggests that daily FVC may be of value as a primary endpoint in short proof-of-concept IPF studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“it is noteworthy that hospital-based FVC measurements, compared with unsupervised daily home measurements, have been suggested to be less sensitive in detecting progression of fibrosis and in predicting subsequent prognosis [19].”
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765 · cited 3×
“This gradual decline is punctuated by unheralded, rapid-onset, catastrophic, acute exacerbations in approximately 5 to 8% of patients with IPF per year (2).”
BackgroundResultAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationWells, A. U., Desai, S. R., Rubens, M. B., Goh, N. S. L., Cramer, D., Nicholson, A. G., Colby, T. V., du Bois, R. M., & Hansell, D. M. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2111053 · Cited by 686
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Landmark Analysis at the 25-Year Landmark Point
Dafni, U. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.957951 · Cited by 569 · cited 1×
“By contrast, a landmark analysis (18) of the 12-month rate of change in home-measured FVC (Figure 6B) for those subjects still alive at 12 months demonstrated that a 12-month rate of change of .”
Result
Cited by
Graham, B. L., Steenbruggen, I., Miller, M. R., Barjaktarevic, I. Z., Cooper, B. G., Hall, G. L., Hallstrand, T. S., Kaminsky, D. A., McCarthy, K., McCormack, M. C., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1590st · Cited by 4,305
Maher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina-Molina, M., Axmann, J., Kirchgaessler, K.-U., Samara, K., Gilberg, F., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30341-8 · Cited by 629
Self-citationGrunewald, J., Grutters, J. C., Arkema, E. V., Saketkoo, L. A., Moller, D. R., & Müller-Quernheim, J. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0096-x · Cited by 479
Interstitial Lung Disease: A Review
Maher, T. M. (2024) · JAMA · doi:10.1001/jama.2024.3669 · Cited by 388
Self-citationFibrosing interstitial lung diseases: knowns and unknowns
Cottin, V., Wollin, L., Fischer, A., Quaresma, M., Stowasser, S., & Harari, S. (2019) · European Respiratory Review · doi:10.1183/16000617.0100-2018 · Cited by 336
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Maher, T. M., & Strek, M. E. (2019) · Respiratory Research · doi:10.1186/s12931-019-1161-4 · Cited by 265
“2 Decline in FVC in patients with IPF based on daily home spirometry [10].”
BackgroundSelf-citationBehr, J., Prasse, A., Wirtz, H., Koschel, D., Pittrow, D., Held, M., Klotsche, J., Andreas, S., Claussen, M., Grohé, C., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02279-2019 · Cited by 198
Acute Exacerbation in Interstitial Lung Disease
Leuschner, G., & Behr, J. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00176 · Cited by 171
“In this context, daily home spirometry is a promising clinical tool to follow the clinical course of IPF patients more closely and potentially detect AE-IPF earlier (81).”
BackgroundMethodOrgan, L. A., Duggan, A.-M. R., Oballa, E., Taggart, S. C., Simpson, J. K., Kang’ombe, A. R., Braybrooke, R., Molyneaux, P. L., North, B., Karkera, Y., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1118-7 · Cited by 139
“Although a recent study has demonstrated that daily home spirometry is predictive of disease progression within 3months, there are some potential limitations with this method, particularly long-term compliance [30].”
BackgroundSelf-citationDigital technologies and adherence in respiratory diseases: the road ahead
Blakey, J. D., Bender, B. G., Dima, A. L., Weinman, J., Safioti, G., & Costello, R. W. (2018) · European Respiratory Journal · doi:10.1183/13993003.01147-2018 · Cited by 136
Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial
Moor, C. C., Mostard, R. L. M., Grutters, J. C., Bresser, P., Aerts, J. G. J. V., Chavannes, N. H., & Wijsenbeek, M. S. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202002-0328oc · Cited by 147
Sullivan, D. R., Iyer, A. S., Enguidanos, S. M., Cox, C. E., Farquhar, M. C., Janssen, D. J. A., Lindell, K. O., Mularski, R. A., Smallwood, N., Turnbull, A. E., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202207-1262st · Cited by 153
Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
Khor, Y. H., Ng, Y., Barnes, H., Goh, N. S. L., McDonald, C. F., & Holland, A. E. (2020) · European Respiratory Review · doi:10.1183/16000617.0158-2019 · Cited by 127
Johannson, K. A., Vittinghoff, E., Morisset, J., Wolters, P. J., Noth, E. M., Balmes, J. R., & Collard, H. R. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.01.015 · Cited by 120
Integrative analysis of cell state changes in lung fibrosis with peripheral protein biomarkers
Mayr, C. H., Simon, L. M., Leuschner, G., Ansari, M., Schniering, J., Geyer, P. E., Angelidis, I., Strunz, M., Singh, P., Kneidinger, N., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012871 · Cited by 106
Home monitoring in interstitial lung diseases
Wijsenbeek, M. S., Moor, C. C., Johannson, K. A., Jackson, P. D., Khor, Y. H., Kondoh, Y., Rajan, S. K., Tabaj, G. C., Varela, B. E., van der Wal, P., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00228-4 · Cited by 98
Self-citationWuyts, W. A., Wijsenbeek, M., Bondue, B., Bouros, D., Bresser, P., Robalo Cordeiro, C., Hilberg, O., Magnusson, J., Manali, E. D., Morais, A., et al. (2020) · Respiration · doi:10.1159/000504763 · Cited by 96
Evaluating disease severity in idiopathic pulmonary fibrosis
Robbie, H., Daccord, C., Chua, F., & Devaraj, A. (2017) · European Respiratory Review · doi:10.1183/16000617.0051-2017 · Cited by 93
Addressing Reduced Laboratory-Based Pulmonary Function Testing During a Pandemic
Kouri, A., Gupta, S., Yadollahi, A., Ryan, C. M., Gershon, A. S., To, T. M., Tarlo, S. M., Goldstein, R. S., Chapman, K. R., & Chow, C. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.06.065 · Cited by 103
“to monitor spirometry weekly, more frequently than is feasible using laboratory-based measurements, offers advantages in some settings where early detection of problems is important—pulmonary fibrosis monitoring and lung transplant surveillance are two established examples.(39,40)”
Moor, C. C., Wapenaar, M., Miedema, J. R., Geelhoed, J. J. M., Chandoesing, P. P., & Wijsenbeek, M. S. (2018) · Respiratory Research · doi:10.1186/s12931-018-0810-3 · Cited by 88
“studies using daily handheld spirometry have been performed in patients with IPF [2, 3].”
BackgroundMethodResultHome monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis
Johannson, K. A., Vittinghoff, E., Morisset, J., Lee, J. S., Balmes, J. R., & Collard, H. R. (2017) · European Respiratory Journal · doi:10.1183/13993003.02406-2016 · Cited by 101
Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes
Saketkoo, L. A., Russell, A., Jensen, K., Mandizha, J., Tavee, J. O., Newton, J. J., Rivera, F., Howie, M., Reese, R. K., Goodman, M., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11061089 · Cited by 94
“[34,35], can offset multi‐factorial burdens on patients/family members.”
BackgroundInfluentialSelf-citationThe Management of Patients With Idiopathic Pulmonary Fibrosis
Spagnolo, P., Tzouvelekis, A., & Bonella, F. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00148 · Cited by 72
“Recently, Russell and colleagues have shown that unsupervised daily home spirometry is a feasible and clinically informative tool for monitoring disease behavior in patients with IPF (112).”
BackgroundPrognosis and Follow-Up of Idiopathic Pulmonary Fibrosis
Fabrellas, E. F., Sánchez, R. P., Abad, C. S., & Samper, G. J. (2018) · Medical Sciences · doi:10.3390/medsci6020051 · Cited by 88
“Recently, more frequent monitoring of lung function by daily home spirometry is being explored as a way to identify acute exacerbations more rapidly as well as worsening of disease [50].”
BackgroundSurvey of Transfer Learning Approaches in the Machine Learning of Digital Health Sensing Data
Chato, L., & Regentova, E. E. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13121703 · Cited by 81
Exploring the 175-year history of spirometry and the vital lessons it can teach us today
Kouri, A., Dandurand, R., Usmani, O., & Chow, C. (2021) · European Respiratory Review · doi:10.1183/16000617.0081-2021 · Cited by 51
Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial
Noth, I., Cottin, V., Chaudhuri, N., Corte, T. J., Johannson, K. A., Wijsenbeek, M. S., Jouneau, S., Michael, A., Quaresma, M., Rohr, K. B., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.01518-2020 · Cited by 71
“Lung function has traditionally been measured periodically in a clinic-based setting, supervised by trained clinicians, but measurements obtained at home using a hand-held device have been shown to correlate well with clinic-based measurements over a 3 – 12-month period [4 – 8].”
InfluentialSelf-citationHome self-monitoring in patients with asthma using a mobile spirometry system
Kupczyk, M., Hofman, A., Kołtowski, Ł., Kuna, P., Łukaszyk, M., Buczyłko, K., Bodzenta‐Łukaszyk, A., Nastałek, P., Soliński, M., & Dąbrowiecki, P. (2019) · Journal of Asthma · doi:10.1080/02770903.2019.1709864 · Cited by 60
“The AioCareR system could also be used for spirometry monitoring in other lung diseases such as chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis, in which daily home spirometry helps to detect disease progression (16).”
MethodMaher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina‐Molina, M., Axmann, J., Kirchgaessler, K.-U., & Cottin, V. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000289 · Cited by 62
“more, FVC decline will not be linear in every patient, as demonstrated by Russell et al.(35) However, in the absence”
BackgroundMethodInfluentialSelf-citationWearable In-Ear PPG: Detailed Respiratory Variations Enable Classification of COPD
Davies, H. J., Bächtiger, P., Williams, I., Molyneaux, P. L., Peters, N. S., & Mandic, D. P. (2022) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2022.3145688 · Cited by 56
“This change in duty cycle is a major difference seen in obstructive lung disease when compared to restrictive lung diseases such as idiopathic pulmonary fibrosis (IPF), where, due to the restriction to both inspiration and expiration, the FEV 1 /FVC remains higher [35].”
BackgroundSelf-citationThe role of tele-medicine in patients with respiratory diseases
Ambrosino, N., & Fracchia, C. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1383898 · Cited by 46
“Following an earlier study of self-monitoring [38], a study investigated the reliability, feasibility, and”
MethodJoint Indian Chest Society-National College of Chest Physicians (India) guidelines for spirometry
Aggarwal, A. N., Agarwal, R., Dhooria, S., Prasad, K. T., Sehgal, I. S., Muthu, V., Singh, N., Behera, D., Jindal, S. K., Singh, V., et al. (2019) · Lung India · doi:10.4103/lungindia.lungindia_300_18 · Cited by 46
“119-121] Antifibrotic agents which decrease the rate of decline in FVC may be associated with a reduction in mortality in IPF.”
Podolanczuk, A. J., Kim, J. S., Cooper, C. B., Lasky, J. A., Murray, S., Oldham, J. M., Raghu, G., Flaherty, K. R., Spino, C., Noth, I., et al. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02281-8 · Cited by 52
“Home spirometry has been shown to be feasible and practical in tracking disease severity and progression in patients with IPF [34, 40].”
Self-citationFlaherty, K. R., Kolb, M., Vancheri, C., Tang, W., Conoscenti, C. S., & Richeldi, L. (2018) · European Respiratory Journal · doi:10.1183/13993003.02593-2017 · Cited by 43
Veit, T., Barnikel, M., Crispin, A., Kneidinger, N., Ceelen, F., Arnold, P., Munker, D., Schmitzer, M., Barton, J., Schiopu, S., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-01524-8 · Cited by 53
Edwards, C. C., Costello, E., Cassidy, N., Vick, B., & Russell, A. (2020) · JMIR mhealth and uhealth · doi:10.2196/16158 · Cited by 44
“Patient-reported spirometry in patients with IPF has been evaluated and found to be feasible in other studies and, in general, it showed good correlation with clinic-measured spirometry [6,7].”
Self-citationEffects of nintedanib by inclusion criteria for progression of interstitial lung disease
Maher, T. M., Brown, K. K., Kreuter, M., Devaraj, A., Walsh, S. L. F., LANCASTER, L. H., Belloli, E. A., Padilla, M. L., Behr, J., Goeldner, R.-G., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.04587-2020 · Cited by 49
“A prospective study based on home spirometry found that in the majority of patients, decline in FVC was almost linear [23].”
Self-citationAnand, R., McLeese, R. H., Busby, J., Stewart, J. E., Clarke, M. J., Man, W. D., & Bradley, J. M. (2023) · European Respiratory Review · doi:10.1183/16000617.0248-2022 · Cited by 41
“Studies included four distinct patient cohorts: interstitial lung disease (n=10) [35, 41, 43 – 48, 54, 58], transplant (n=8) [36, 38, 42, 49, 51, 56, 57, 59], obstructive airways disease (n=5) [19, 39, 40, 50, 53] and suppurative lung disease (n=5) [30, 34, 37, 52, 55].”
InfluentialDigital twins for chronic lung diseases
Gonsard, A., Genet, M., & Drummond, D. (2024) · European Respiratory Review · doi:10.1183/16000617.0159-2024 · Cited by 55
Sharp, C., Adamali, H. I., & Millar, A. B. (2017) · ERJ Open Research · doi:10.1183/23120541.00096-2016 · Cited by 41
Self-citationMobile Health Monitoring in Patients with Idiopathic Pulmonary Fibrosis
Marcoux, V. S., Wang, M., Burgoyne, S., Fell, C. D., Ryerson, C. J., Sajobi, T. T., & Johannson, K. A. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201904-335rl · Cited by 41
Hendriks, C., Saketkoo, L. A., Elfferich, M., Vries, J. D., Wijnen, P. A. H. M., & Drent, M. (2019) · Lung · doi:10.1007/s00408-019-00234-3 · Cited by 42
Home monitoring for patients with ILD and the COVID-19 pandemic
Nakshbandi, G., Moor, C. C., & Wijsenbeek, M. S. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30452-5 · Cited by 43
Feasibility of a Comprehensive Home Monitoring Program for Sarcoidosis
Moor, C. C., Gür-Demirel, Y., & Wijsenbeek, M. S. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9020023 · Cited by 39
“Other studies using home spirometry in sarcoidosis and pulmonary fibrosis showed comparable results regarding correlation with hospital FVC, reproducibility, and overall lower results for home spirometry [14,15,26].”
ResultFainberg, H. P., Oldham, J. M., Molyneaux, P. L., Allen, R. J., Kraven, L. M., Fahy, W. A., Porte, J., Braybrooke, R., Saini, G., Karsdal, M. A., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00173-x · Cited by 46
“22,23 However, in these studies, a degree of heterogeneity exists that is not observed by regression to the mean, even in home spirometry studies that are often limited to short durations.”
Self-citationOhkubo, H., Nakagawa, H., & Niimi, A. (2017) · Respiratory Investigation · doi:10.1016/j.resinv.2017.10.003 · Cited by 44
Moor, C. C., van Leuven, S. I., Wijsenbeek, M. S., & Vonk, M. C. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa607 · Cited by 42
Turner, J., He, Q., Baker, K., Chung, L., Lazarevic-Fogelquist, A., Bethune, D., Hubbard, J. J., Guerriero, M., Sheshadri, A., Syrjala, K. L., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.03.024 · Cited by 36
Johannson, K. A., Lethebe, B. C., Assayag, D., Fisher, J. H., Kolb, M. R. J., Morisset, J., Shapera, S., Gershon, A. S., Hambly, N., Khalil, N., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202102-216oc · Cited by 40
The Current and Future Role of Technology in Respiratory Care
Honkoop, P., Usmani, O. S., & Bonini, M. (2022) · Pulmonary Therapy · doi:10.1007/s41030-022-00191-y · Cited by 46
“Following an earlier report of self-monitoring of pulmonary function using a home spirometer, [44] a study investigated the reliability, feasibility, and impact of home-based measurement of forced vital capacity (FVC) and dyspnea in a US population of IPF patients [45].”
MethodClinical course and management of idiopathic pulmonary fibrosis
Quinn, C., Wisse, A., & Manns, S. T. (2019) · Multidisciplinary Respiratory Medicine · doi:10.1186/s40248-019-0197-0 · Cited by 46
Althobiani, M. A., Evans, R., Alqahtani, J. S., Aldhahir, A. M., Russell, A., Hurst, J. R., & Porter, J. C. (2021) · ERJ Open Research · doi:10.1183/23120541.00441-2021 · Cited by 37
“Russell et al.[33] reported 18 deaths out of 50”
BackgroundInfluentialSelf-citationNathan, S. D., Wanger, J. S., Zibrak, J. D., Wencel, M. L., Burg, C., & Stauffer, J. L. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1816831 · Cited by 38
Mechanisms of Bleomycin-induced Lung Fibrosis: A Review of Therapeutic Targets and Approaches
Mohammed, S. M., Al-Saedi, H. F. S., Mohammed, A. Q., Amir, A. A., Radi, U. K., Sattar, R., Ahmad, I., Ramadan, M. F., Alshahrani, M. Y., Balasim, H. M., et al. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01384-9 · Cited by 46
“This includes measuring improvements in lung function, reduction in fi brotic tissue, and overall quality of life [247, 248].”
Risk factors for disease progression in idiopathic pulmonary fibrosis
Raghu, G., Ley, B., Brown, K. M., Cottin, V., Gibson, K. F., Kaner, R. J., Lederer, D. J., Noble, P. W., Song, J. W., Wells, A. U., et al. (2019) · Thorax · doi:10.1136/thoraxjnl-2019-213620 · Cited by 35
Self-citationQuality of home spirometry performance amongst adults with cystic fibrosis
Bell, J. M., Sivam, S., Dentice, R. L., Dwyer, T., Jo, H. E., Lau, E. M., Munoz, P. A., Nolan, S. A., Taylor, N. A., Visser, S. K., et al. (2021) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2021.10.012 · Cited by 31
Maher, T. M., Schiffman, C., Kreuter, M., Moor, C. C., Nathan, S. D., Axmann, J., Belloni, P., Bengus, M., Gilberg, F., Kirchgaessler, K.-U., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02221-4 · Cited by 38
Self-citationIntegrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis
Moor, C. C., Heukels, P., Kool, M., & Wijsenbeek, M. S. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00226 · Cited by 34
“Recently, a study showed that daily home spirometry in a population of patients with IPF was highly feasible and informative (94).”
BackgroundKhan, F., Howard, L., Hearson, G., Edwards, C., Barber, C., Jones, S., Wilson, A. M., Maher, T. M., Saini, G., Stewart, I., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202105-612rl · Cited by 31
Self-citationAlthobiani, M. A., Alqahtani, J. S., Hurst, J. R., Russell, A., & Porter, J. C. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001088 · Cited by 38
Self-citationWong, A. M., Lu, J., Dorfman, A., McInnis, P., Famouri, M., Manary, D., Lee, J. R. H., & Lynch, M. (2021) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2021.764047 · Cited by 34
“For example, spirometry tests are frequently leveraged for measuring the FVC of the lung which is a key indicator of lung function [7, 8, 9, 10].”
BackgroundMoor, C. C., van den Berg, C. A. L., Visser, L., Aerts, J. G. J. V., Cottin, V., & Wijsenbeek, M. S. (2020) · ERJ Open Research · doi:10.1183/23120541.00054-2020 · Cited by 33
Макановна, М. Ж., Dinmukhamedova, A. S., Kabieva, S., Baidalinova, B., Khamzina, S., Zekenova, L., & Айзман, Р. И. (2022) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2022-0474 · Cited by 39
Khor, Y. H., Poberezhets, V., Buhr, R. G., Chalmers, J. D., Choi, H., Fan, V. S., George, M., Holland, A. E., Pinnock, H., Ryerson, C. J., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202410-2080st · Cited by 36
Rackow, A. R., Nagel, D. J., McCarthy, C., Judge, J., Lacy, S. H., Freeberg, M. A. T., Thatcher, T. H., Kottmann, R. M., & Sime, P. J. (2020) · European Respiratory Journal · doi:10.1183/13993003.00075-2020 · Cited by 31
Lung function trajectories in patients with idiopathic pulmonary fibrosis
Neely, M. L., Hellkamp, A. S., Bender, S. D., Todd, J. L., Liesching, T. N., Luckhardt, T., Oldham, J. M., Raj, R., White, E. S., & Palmer, S. M. (2023) · Respiratory Research · doi:10.1186/s12931-023-02503-5 · Cited by 32
Holistic management of patients with progressive pulmonary fibrosis
Oliveira, A., Fabbri, G., Gille, T., Bargagli, E., Duchemann, B., Evans, R. A., Pinnock, H., Holland, A. E., Renzoni, E. A., Ekström, M. P., et al. (2023) · Breathe · doi:10.1183/20734735.0101-2023 · Cited by 28
“Single centre studies have shown that data acquired from home is reliable when compared with hospital spirometry [82 – 84].”
ResultSelf-citationEvaluating a Remote Monitoring Program for Respiratory Diseases: Prospective Observational Study
Althobiani, M. A., Ranjan, Y., Jacob, J., Orini, M., Dobson, R., Porter, J. C., Hurst, J. R., & Folarin, A. (2023) · JMIR Formative Research · doi:10.2196/51507 · Cited by 25
“In contrast, previous studies have used alternative data storage methods such as handwritten diary cards and manual downloads for which adherence rates were not reported and quality checks were not applicable [58,59].”
ResultHow COVID-19 interacts with interstitial lung disease
Myall, K. J., Martinovic, J. L., & West, A. (2022) · Breathe · doi:10.1183/20734735.0158-2021 · Cited by 26
Lee, J. Y. T., Tikellis, G., Glaspole, I., Khor, Y. H., Symons, K., & Holland, A. E. (2021) · Patient Education and Counseling · doi:10.1016/j.pec.2021.07.005 · Cited by 25
Mandizha, J., Lanario, J. W., Duckworth, A., Lines, S., Paiva, A., Elworthy, V., Muraleedharan, V., Ponte, A. J. D., Shuttleworth, R., Brown, G., et al. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2023-001837 · Cited by 21
Self-citationNyilas, S., Schreder, T., Singer, F., Poellinger, A., Geiser, T., Latzin, P., & Funke, M. (2018) · Respirology · doi:10.1111/resp.13294 · Cited by 21
Wijsenbeek, M. S., Bendstrup, E. M., Valenzuela, C., Henry, M. T., Moor, C. C., Bengus, M., Perjesi, A., Gilberg, F., Kirchgaessler, K.-U., & Vancheri, C. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0845-3 · Cited by 20
Montesi, S. B., Gómez, C. R., Beers, M. F., Brown, R., Chattopadhyay, I., Flaherty, K. R., Garcia, C. K., Gomperts, B. N., Hariri, L. P., Hogaboam, C. M., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202307-1154ws · Cited by 21
Self-citationBoente, R., Schacht, S., Borton, R., Vincent, J., Golzarri‐Arroyo, L., & Rattray, N. A. (2024) · Respiratory Research · doi:10.1186/s12931-024-02735-z · Cited by 21
“Furthermore, other studies have shown that daily spirometry allows for quicker evaluation of clinical deterioration and that daily spirometry can detect variability in FVC, which is linked to disease progression in ILD [27, 28].”
Maher, T. M., Stowasser, S., Nishioka, Y., White, E. S., Cottin, V., Noth, I., Selman, M., Blahova, Z., Wachtlin, D., Diefenbach, C., et al. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000325 · Cited by 18
“In addition, more frequent measurement of FVC at home may enable early detection of rapidly declining FVC, thereby enabling early identification of patients with disease progression or an acute exacerbation.(38) In two small studies conducted to examine the feasibility and reliability of using home spirometry in patie…”
ResultSelf-citationEvaluation of m‐Health‐rehabilitation for respiratory disorders: A systematic review
Kiani, S., Abasi, S., & Yazdani, A. (2022) · Health Science Reports · doi:10.1002/hsr2.575 · Cited by 22
“The use of spirometry seems to be because studies have shown that daily home spirometry is an effective tool for diagnosing the progression of idiopathic pulmonary fibrosis and is involved in the early diagnosis of infection.(55) Also, in some patients, such as those with asthma, repeated measurements of pulmonary fun…”
MethodAlthobiani, M. A., Russell, A., Jacob, J., Ranjan, Y., Ahmad, R., Folarin, A., Hurst, J. R., & Porter, J. C. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1361667 · Cited by 22
Self-citationKerwin, E., Pascoe, S. J., Bailes, Z., Nathan, R. A., Bernstein, D., Dahl, R., von Maltzahn, R., Robbins, K., Fowler, A. V., & Lee, L. A. (2020) · Respiratory Research · doi:10.1186/s12931-020-01400-5 · Cited by 16
Wijsenbeek, M. S., Molina‐Molina, M., Chassany, O., Fox, J., Galvin, L., Geissler, K. H., Hammitt, K. M., Kreuter, M., Moua, T., O'Brien, E. C., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00681-2021 · Cited by 18
“Future considerations that warrant further discussion include wearable technologies [31] to supplement PROMs by recording response data ( e.g. physical activity) [32 – 34].”
Khan, F., Stewart, I. D., Howard, L., McKeever, T. M., Jones, S., Hearson, G., Braybrooke, R., Edwards, C. C., Jenkins, G. R., & Saini, G. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2019-000439 · Cited by 17
“Our understanding of IPF has improved significantly both in terms of biomarkers(7) 8 and clinical end points.(9) However, there remains a significant gap in our understanding of non-IPF ILD, with currently no approved treatments or cure.”
BackgroundGarcía-Fernández, F., Marchena‐Gómez, J., Morán, V. C., Hermida, M. I. G., Sotgiu, E., & Pérez, G. V. (2011) · PubMed · Cited by 14
Fujii, H., Hara, Y., Saigusa, Y., Tagami, Y., Murohashi, K., Nagasawa, R., Aoki, A., Izawa, A., Seki, K., Watanabe, K., et al. (2023) · Canadian Respiratory Journal · doi:10.1155/2023/5088207 · Cited by 21
Care Delivery Models and Interstitial Lung Disease
Fisher, J. H., & Cottin, V. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.013 · Cited by 15
Johnson, J., Stewart, I. D., & Johnson, S. R. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-217809 · Cited by 13
Oishi, K., Hirano, T., Murata, Y., Hamada, K., Uehara, S., Suetake, R., Yamaji, Y., Asami‐Noyama, M., Edakuni, N., Ohata, S., et al. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619872890 · Cited by 16
Pesonen, I., Gao, J., Kalafatis, D., Carlson, L., Sköld, M. C., & Ferrara, G. (2020) · Respiratory Medicine X · doi:10.1016/j.yrmex.2020.100017 · Cited by 18
Johannson, K. A. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202005-1532ed · Cited by 16
“estimate of change to delineate clinical trajectory and may allow for earlier intervention and prognostication (9, 10).”
BackgroundPatient-centered care in pulmonary fibrosis: access, anticipate, and act
Hofman, D. E., Magrì, T., Moor, C. C., Richeldi, L., Wijsenbeek, M. S., & Waseda, Y. (2024) · Respiratory Research · doi:10.1186/s12931-024-02997-7 · Cited by 15
Home Spirometry in Children with Cystic Fibrosis
Berlinski, A., Leisenring, P., Willis, L. C., & King, S. E. (2023) · Bioengineering · doi:10.3390/bioengineering10020242 · Cited by 13
Aggarwal, R., Oddis, C. V., Sullivan, D. I., Moghadam‐Kia, S., Saygın, D., Kass, D. J., Koontz, D. C., Li, P., Conoscenti, C., Olson, A. L., et al. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03314-0 · Cited by 15
“Moderate to strong cross-sectional correlations between home-and clinic-based measurements have been demonstrated [40–44], but issues with the reliability and variability of home-based measurements have been observed [42, 45, 46].”
BackgroundAlthobiani, M. A., Shuttleworth, R., Conway, J., Dainton, J., Duckworth, A., Ponte, A. J. D., Mandizha, J., Lanario, J. W., Gibbons, M., Lines, S., et al. (2024) · PLOS Digital Health · doi:10.1371/journal.pdig.0000318 · Cited by 10
Self-citationIlic, M. P., Javorac, J., Milenković, A., Živanović, D., Miljković, D., Kašiković-Lečić, S., Savić, N., Vereš, K. T., Kovačević, D., Vujičić, E., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050793 · Cited by 11
“The first studies comparing the efficacy of home and office-based spirometers in ILDs appeared between 2016 and 2017 [7,9].”
BackgroundRole of the internet of medical things in care for patients with interstitial lung disease
Nakshbandi, G., Moor, C. C., & Wijsenbeek, M. S. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000971 · Cited by 11
“The first studies, in patients with IPF, used paper diaries to collect home spirometry results, which hampers use in clinical practice [18,20].”
ResultTracking dyspnea up to supplemental oxygen prescription among patients with pulmonary fibrosis
Olson, A. L., Graney, B. A., Baird, S. J., Churney, T., Fier, K., Korn, M., McCormick, M., Sprunger, D. B., Vierzba, T., Wamboldt, F. S., et al. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0497-0 · Cited by 11
“Collecting quantitative dyspnea data more frequently from PF patients could potentially, like daily spirometry [12], alert patients and practitioners to PF acceleration, prompt urgent evaluation and trigger timely intervention.”
BackgroundModelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
Santermans, E., Ford, P., Kreuter, M., Verbruggen, N., Meyvisch, P., Wuyts, W. A., Brown, K. K., Lederer, D. J., Byrne, A. J., Molyneaux, P. L., et al. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01093-3 · Cited by 8
Self-citationCombination Therapy and the Start of a New Epoch for Idiopathic Pulmonary Fibrosis?
Maher, T. M. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201709-1939ed · Cited by 9
Self-citationBarth, S. E., Edwards, C. C., Saini, G., Haider, Y., Williams, N., Storrar, W., Jenkins, G. R., Stewart, I. D., & Wickremasinghe, M. I. Y. (2024) · Respiratory Research · doi:10.1186/s12931-024-02787-1 · Cited by 15
“…that remotely recorded spirometry measurements correlate well with hospital-based spirometry measurements for both participants with IPF [9] and non-IPF ILDs [19], whilst feasibility in asking participants to record remote spirometry on a daily or weekly basis has been demonstrated…”
BackgroundMethodResultOn Treatments and Tests Deferred: Preparing for Collateral Damage from COVID-19
Jain, S., & Santhosh, L. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202004-387vp · Cited by 8
Singer, D., Bengtson, L. G. S., Conoscenti, C., Anderson, A. J., Brekke, L. N., Shetty, S. S., & de Andrade, J. A. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2054203 · Cited by 8
Metadata
- Authors
- Russell, A.-M., Adamali, H., Molyneaux, P. L., Lukey, P. T., Marshall, R. P., Renzoni, E. A., Wells, A. U., & Maher, T. M.
- Affiliations
- National Institute for Health and Care Research (GB)
- Southmead Hospital (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- Maher, Toby M.
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10
- Volume
- 194
- Issue
- 8
- Pages
- 989-997
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC5067818
- OpenAlex
- W2336917368
- Cited by
- 178
- References
- 26
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 20 · 2023: 18 · 2022: 23 · 2021: 22 · 2020: 17 · 2019: 22 · 2018: 17 · 2017: 15 · 2016: 4
- FWCI
- 17.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- U.S. Department of Veterans Affairs (CDA13-017)
- Royal Brompton and Harefield NHS Foundation Trust
- National Institute for Health and Care Research (PB-PG-0712-28073, CS-2013-13-017, CDRF-2012-03-053)
- Imperial College London
- Versus Arthritis (20719)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, home spirometry, disease progression, mortality prediction, primary endpoint
- MeSH terms
- Aged, Female, Humans, Male, Self Care, Spirometry, Time Factors, Vital Capacity, Proportional Hazards Models, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.